FINWIRES · TerminalLIVE
FINWIRES

SHA:688331

5 stories mentioning SHA:688331

Every FINWIRES story that references SHA:688331, newest first.

Asia

RemeGen Gets China Marketing Nod for Telitacicept Injection for IgA Nephropathy Indication

RemeGen (HKG:9995, SHA:688331) obtained a drug registration certificate and conditional marketing approval for a new indication of Telitacicept Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The new indication of the drug is for the treatment of IgA nephropathy, or to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.

HKG:9995SHA:688331
Asia

RemeGen Gets Marketing Nod for Sjögren's Syndrome Drug in China

RemeGen (HKG:9995, SHA:688331) obtained a drug registration certificate and marketing approval for a new indication of Telitacicept for Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The new indication of the drug is for the treatment of Sjögren's syndrome, the biopharmaceutical company said.

HKG:9995SHA:688331
Asia

Junshi Biosciences Gets Nod for New Indication for Toripalimab; Shares Down 4%

Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received a drug registration certificate from China's National Medical Products Administration for a new indication for toripalimab, according to a Hong Kong bourse filing on Thursday.The pharmaceutical company's Shanghai shares dropped by less than 4%, while Hong Kong shares fell by less than 2% during Friday's morning trade.The drug, which trades as Tuoyi, will be allowed for the treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma in combination with disitamab vedotin, an antibody drug conjugate developed by RemeGen (HKG:9995, SHA:688331).

HKG:1877HKG:9995SHA:688180SHA:688331
Asia

RemeGen Invests in Wealth Management Products

RemeGen (HKG:9995, SHA:688331) said it invested in various wealth management products offered by Huatai Securities, according to a Friday filing with the Hong Kong bourse.The biopharmaceutical company invested 60 million yuan in a fixed-income product that invests in debt assets, 75 million yuan in another fixed-income product that covers liquid financial instrument, and a further 102 million yuan in a fixed-income product tied to financial products and cash-type assets.The company also invested 216 million yuan in a ten-year product that will be invested in financial products and cash-type assets.The firm said the products will help "revitalize idle funds."

HKG:9995SHA:688331
Asia

RemeGen Swings to Profit in Q1 2026

RemeGen (HKG:9995, SHA:688331) booked 328 million yuan in attributable profit for the first quarter of 2026, swinging from a loss of 254.1 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The biopharmaceutical company's Hong Kong shares were down 2% in late morning trade Wednesday.Earnings per share were 0.58 yuan, compared with a loss of 0.46 year in the prior year period.Operating revenue jumped 25% year on year to 656.2 million yuan, figures showed.

HKG:9995SHA:688331